CollabRx, Inc, a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA’s cancer mutation panels. Read more

With over 30 million worldwide blog sites analyzed, the study provides fascinating insights into emotions by stage of cancer and emotions surrounding key drugs prescribed in head and neck, ovarian, breast, lung, colorectal, hepatocellular and renal cancers. It also identifies key opinion leaders(KOP’s) and influencers across the blogosphere.

In addition, the study has classified every Oncology drug mentioned across the blogosphere for its intensity of mention by category of disease. Key metrics such as emotions over time for competitive oncology drugs, emotions around treatment type (medication, radiation, surgery, etc.) as well as cohorts of physicians, patients, nurses and caregivers were analyzed. BehaviorMatrix presented findings around one of the disease categories studied, breast cancer, at the ePharma Summit. Read more

According to a new article out of the company, “CollabRx, Inc. today announced the release of a new version of its Therapy Finder™ application (‘app’) for lung cancer. The lung cancer Therapy Finder™app is a web-based decision support tool that enables oncologists to take into account the genetics of a patient’s tumor when determining a treatment plan. The newest lung cancer Therapy Finder™ is currently freely available at the company’s website and via distribution partners such as MedPage Today, Everyday Health’s physician portal (http://www.medpagetoday.com/resource-center/lung-cancer-therapy/therapy-finder).” Read more